Business
N4 101 In Vivo Study Results
N4 101 In Vivo Study Results.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n\n \n12 May 2025\n \nN4 Pharma plc\n \n(\"N4 Pharma\" or the \"Company\")\n \nN4 101 In Vivo Study Results\n \nPositive results from first in vivo study of dual-loaded Nuvec® for IBD\n \nN4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce positive results from its first in vivo study evaluating the use of its Nuvec® proof-of-concept programme, N4 101, an orally delivered anti-inflammatory treatment for Inflammatory Bowel Disease (IBD).\n \nFollowing the successful completion of in vitro profiling in December 2024, N4 Pharma has now completed its first in vivo study using an industry-standard mouse model of IBD. The study explored the therapeutic potential of orally administered Nuvec® particles loaded with siRNA alone and combined with mRNA.\n \nOver a nine-day dosing period, mice with chemically induced acute IBD received single (siRNA) or dual (siRNA and mRNA) Nuvec®-loaded formulations, and versions of these therapies specifically targeted at cells involved in gut inflammation using modified Nuvec® particles. Samples were collected for analysis on day 15.\n \nKey highlights from the study include:\n \n\n\n\n\n• \n\n\nReduction in inflammation: both single and dual-loaded Nuvec® particles demonstrated marked improvements compared with controls across all key indicators of colitis, including Disease Activity Index (DAI), colon length, and body weight loss.\n\n\n\n\n• \n\n\nMarked increase in efficacy achieved with targeting: both the single and dual loaded Nuvec® combined with a targeting agent performed better and showed an even greater reduction in the inflammatory marker TNF alpha than the untargeted therapies.\n\n\n\n\n• \n\n\nSustained therapeutic effect: six days after the final administration, both single and dual-loaded targeted Nuvec® particles showed a near complete reduction in TNF alpha levels in intestinal tissues.\n\n\n\n\n• \n\n\nEffective oral delivery: the study also provides clear in vivo evidence that Nuvec® particles successfully deliver therapeutic nucleic acid cargos (siRNA and mRNA) to the gut via oral administration, resulting in the sustained anti-inflammatory effects ...